Perfil de Segurança de Baricitinib em Pacientes Japoneses com Artrite Reumatoide Ativa com mais de 1.6 Anos de Tempo Médio de Tratamento: Uma Analise Integrada de Ensaios Fase 2 e 3.
Mod Rheumatol. 2019 Feb 20:1-23. DOI: 10.1080/14397595.2019.1583711
In this integrated analysis, BARI showed an acceptable safety profile in Japanese patients with up to 3.2 years of exposure. Other than incidences of herpes zoster (HZ), no major differences were noted with BARI safety in Japanese patients with RA, compared to the patients in the integrated database.BARI has previously demonstrated significant clinical efficacy and acceptable safety. Japanese patients who participated in the BARI clinical development programme, were comparable to those from the ...